Market Overview

UPDATE: Jefferies Upgrades Pfizer from Hold to Buy, Boosts Target to $38

Related PFE
6 Big Pharma Companies Left To Report September Quarterly Figures
Pfizer's Medivation Receives FDA Approval For Prostate Cancer Drug XTANDI
Myovant Sciences IPO Attracts Major Pharma Interest (Seeking Alpha)

Pfizer (NYSE: PFE) has received an upgraded rating from Hold to Buy and a raised price target from $33 to $38 at Jefferies Tuesday morning.

Pfizer's upgrades follows acknowledgments that Oncology and restructuring are key themes for the Pharma sector and Pfizer has both of those covered with palbociclib looking like it could launch before year end, according to the firm's Jeffery Holland.

The Jefferies analyst expects the market to soon be reflecting incremental value in the shares based on the drivers above, adding significant upside to the companies shares.

Shares of Pfizer are up 2.7 percent to $31.42 at last check following the upgrade.

Latest Ratings for PFE

Oct 2016JefferiesDowngradesBuyHold
Sep 2016JefferiesMaintainsBuy
Aug 2016JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades Price Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!